First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele.

doi:10.1016/j.cca.2013.05.008

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele.

Clinica chimica acta; international journal of clinical chemistry - 23 Sept 2013

O'Brien Travis J, Kidd Robert S, Richard Craig A H, Ha Ngoc-Han, Witcher Preston, Tran Linda V, Barbour April, Tuck Matthew, McIntosh Samantha D, Douglas Jacqueline N, Harralson Arthur F

Abstract excerpt

BACKGROUND: Warfarin is the most frequently prescribed anticoagulant in North America and Europe. It is administered as a racemate, but S-warfarin is principally responsible for its anticoagulant activity. Cytochrome P450 (CYP) 2C9 is the enzyme primarily responsible for the metabolism of S-warfarin. Numerous variant alleles of CYP2C9 have been identified. The CYP2C9*12 (rs9332239) allele harbors a P489S...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aryl Hydrocarbon Hydroxylases

Share to Biotransformation

Share to Cytochrome P-450 CYP2C9

Share to Drug Dosage Calculations

Share to Thromboembolism

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Open in PubMed

Identifiers

PMID: 23688605
DOI: 10.1016/j.cca.2013.05.008

Genes

APOE
VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele.PMID 23688605Read ↗

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.Semantic proximity Read ↗

Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis.Semantic proximity Read ↗

Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.Semantic proximity Read ↗

CYP2C9*8 is Prevalent Among African–Americans: Implications for Pharmacogenetic DosingSemantic proximity Read ↗

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.Semantic proximity Read ↗

Warfarin dose requirements in a patient with the CYP2C9*14 allele.Semantic proximity Read ↗

VKORC1 and CYP2C9 genotype distribution in Asian countries.Semantic proximity Read ↗

Warfarin dosing and cytochrome P450 2C9 polymorphisms.Semantic proximity Read ↗

Pharmacogenomics of CYP2C9: Functional and Clinical ConsiderationsSemantic proximity Read ↗

Cytochrome P450 polymorphisms are associated with reduced warfarin dose.Semantic proximity Read ↗

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.Semantic proximity Read ↗

Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.